Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | LPL | P06858 | 11/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960738 | 0.88 | ESR2 (0.41) | ESR2PGRLPLLIPG | |
| SCHEMBL587884 | 0.82 | LPL (0.44) | LPLLIPGEGFR | |
| SCHEMBL18015340 | 0.82 | LPL (0.44) | LPLLIPGEGFR | |
| SCHEMBL12327387 | 0.81 | ESR2 (0.37) | ESR2PGRLPLLIPG | |
| SCHEMBL30345343 | 0.80 | ESR2 (0.36) | ESR2LPLLIPG | |
| SCHEMBL3323420 | 0.80 | ESR2 (0.36) | ESR2LPLLIPG | |
| SCHEMBL419330 | 0.80 | LPL (0.45) | ESR2PGRLPLLIPG | |
| SCHEMBL29975527 | 0.80 | ESR2 (0.36) | ESR2LPLLIPG | |
| SCHEMBL4784162 | 0.80 | ESR2 (0.36) | ESR2LPLLIPG | |
| SCHEMBL12522631 | 0.80 | ESR2 (0.36) | ESR2PGRLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | NXERA PHARMA UK LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| EP-4594308-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | Vividion Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2024-03-21 | — | — | US | disclosed |
| CN-112839931-B | 1,2,3, 4-tetrahydroquinoxaline derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2324032-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | ESR2 141/4885PGR 435/4885LPL 1219/4885 |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | ESR2 2144/4885PGR 4654/4885LPL 1639/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | ESR2 141/4885PGR 435/4885LPL 1219/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | ESR2 1734/4885PGR 4241/4885LPL 3942/4885 |
| US-12415795-B2 | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | GRM5, GRM6, GRM2 | ESR2 620/4885PGR 899/4885LPL 1073/4885 |
| US-20240092754-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | ESR2 620/4885PGR 899/4885LPL 1073/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | ESR2 736/4885PGR 4483/4885LPL 2983/4885 |
| US-20110071126-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, PSEN1 | ESR2 1890/4885PGR 4426/4885LPL 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.